July 20, 2022 11:23 AM EDT

Without voluntary withdrawals, ODAC to review two more dangling accelerated approvals

Zachary Brennan

Senior Editor

The FDA’s Oncologic Drugs Advisory Committee will meet over two days in late September to discuss three controversial drugs, two of which have already won …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Without voluntary withdrawals, ODAC to review two more dangling accelerated approvals

Zachary Brennan

Senior Editor

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Why did Eli Lilly ask a patient on a compounded GLP-1 drug for their medical information?

Biotech VC firm outlines plans for $100M fund

Novo says its CB1 drug helped shed weight, but efficacy and safety questions remain

FDA OKs the first-ever self-administered vaccine, for flu

FTC to sue major PBMs over insulin rebates, claiming they inflated patient cost

Breaking down silos with a new quantitative approach to drug development

With­out vol­un­tary with­drawals, ODAC to re­view two more dan­gling ac­cel­er­at­ed ap­provals

Senior Editor

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Without voluntary withdrawals, ODAC to review two more dangling accelerated approvals